Literature DB >> 30598494

Gemtuzumab ozogamicin in acute myeloid leukemia: act 2, with perhaps more to come.

Johann Hitzler1, Elihu Estey2.   

Abstract

Entities:  

Year:  2019        PMID： 30598494      PMCID： PMC6312009          DOI： 10.3324/haematol.2018.205948

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  18 in total

1.  The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia.

Authors:  Guillaume Olombel; Estelle Guerin; Julien Guy; Jean-Yves Perrot; Florent Dumezy; Adrienne de Labarthe; Jean-Noël Bastie; Ollivier Legrand; Emmanuel Raffoux; Adriana Plesa; Orianne Wagner-Ballon; Edouard Cornet; Véronique Salaun; Claude Preudhomme; Xavier Thomas; Cécile Pautas; Sylvain Chantepie; Pascal Turlure; Sylvie Castaigne; Hervé Dombret; Jean Feuillard
Journal:  Blood       Date:  2016-02-29       Impact factor: 22.113

2.  No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC/NCRI trials.

Authors:  Rosemary E Gale; Teodora Popa; Melissa Wright; Naeem Khan; Sylvie D Freeman; Alan K Burnett; Nigel H Russell; Robert K Hills; David C Linch
Journal:  Blood       Date:  2017-12-11       Impact factor: 22.113

3.  CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531.

Authors:  Jessica A Pollard; Michael Loken; Robert B Gerbing; Susana C Raimondi; Betsy A Hirsch; Richard Aplenc; Irwin D Bernstein; Alan S Gamis; Todd A Alonzo; Soheil Meshinchi
Journal:  J Clin Oncol       Date:  2016-01-19       Impact factor: 44.544

4.  Implications of potential cure in acute myelogenous leukemia: development of subsequent cancer and return to work.

Authors:  M de Lima; S S Strom; M Keating; H Kantarjian; S Pierce; S O'Brien; E Freireich; E Estey
Journal:  Blood       Date:  1997-12-15       Impact factor: 22.113

5.  Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project.

Authors:  June M McKoy; Cara Angelotta; Charles L Bennett; Martin S Tallman; Martha Wadleigh; Andrew M Evens; Timothy M Kuzel; Steve M Trifilio; Dennis W Raisch; Jonathan Kell; Daniel J DeAngelo; Francis J Giles
Journal:  Leuk Res       Date:  2006-09-07       Impact factor: 3.156

6.  Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.

Authors:  Sylvie Castaigne; Cécile Pautas; Christine Terré; Emmanuel Raffoux; Dominique Bordessoule; Jean-Noel Bastie; Ollivier Legrand; Xavier Thomas; Pascal Turlure; Oumedaly Reman; Thierry de Revel; Lauris Gastaud; Noémie de Gunzburg; Nathalie Contentin; Estelle Henry; Jean-Pierre Marolleau; Ahmad Aljijakli; Philippe Rousselot; Pierre Fenaux; Claude Preudhomme; Sylvie Chevret; Hervé Dombret
Journal:  Lancet       Date:  2012-04-05       Impact factor: 79.321

Review 7.  Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials.

Authors:  Robert K Hills; Sylvie Castaigne; Frederick R Appelbaum; Jacques Delaunay; Stephen Petersdorf; Megan Othus; Elihu H Estey; Hervé Dombret; Sylvie Chevret; Norbert Ifrah; Jean-Yves Cahn; Christian Récher; Lucy Chilton; Anthony V Moorman; Alan K Burnett
Journal:  Lancet Oncol       Date:  2014-07-06       Impact factor: 41.316

8.  Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia.

Authors:  N Khan; R K Hills; P Virgo; S Couzens; N Clark; A Gilkes; P Richardson; S Knapper; D Grimwade; N H Russell; A K Burnett; S D Freeman
Journal:  Leukemia       Date:  2016-10-31       Impact factor: 11.528

9.  New drug approvals in acute myeloid leukemia: what's the best end point?

Authors:  E Estey; M Othus; S J Lee; F R Appelbaum; R P Gale
Journal:  Leukemia       Date:  2015-12-18       Impact factor: 11.528

10.  Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial.

Authors:  Juliette Lambert; Cécile Pautas; Christine Terré; Emmanuel Raffoux; Pascal Turlure; Denis Caillot; Ollivier Legrand; Xavier Thomas; Claude Gardin; Karïn Gogat-Marchant; Stephen D Rubin; Rebecca J Benner; Pierre Bousset; Claude Preudhomme; Sylvie Chevret; Herve Dombret; Sylvie Castaigne
Journal:  Haematologica       Date:  2018-08-03       Impact factor: 9.941
View more
  4 in total

Review 1.  High-Risk Acute Myeloid Leukemia: A Pediatric Prospective.

Authors:  Fabiana Cacace; Rossella Iula; Danilo De Novellis; Valeria Caprioli; Maria Rosaria D'Amico; Giuseppina De Simone; Rosanna Cuccurullo; William G Wierda; Kris Michael Mahadeo; Giuseppe Menna; Francesco Paolo Tambaro
Journal:  Biomedicines       Date:  2022-06-14

Review 2.  Antibody-Mediated Enzyme Therapeutics and Applications in Glycogen Storage Diseases.

Authors:  Zhengqiu Zhou; Grant L Austin; Robert Shaffer; Dustin D Armstrong; Matthew S Gentry
Journal:  Trends Mol Med       Date:  2019-09-12       Impact factor: 11.951

Review 3.  Patterns of undertreatment among patients with acute myeloid leukemia (AML): considerations for patients eligible for non-intensive chemotherapy (NIC).

Authors:  Elizabeth Hubscher; Slaven Sikirica; Timothy Bell; Andrew Brown; Verna Welch; Alexander Russell-Smith; Paul D'Amico
Journal:  J Cancer Res Clin Oncol       Date:  2021-08-30       Impact factor: 4.553

4.  Uncialamycin-based antibody-drug conjugates: Unique enediyne ADCs exhibiting bystander killing effect.

Authors:  K C Nicolaou; Stephan Rigol; Emmanuel N Pitsinos; Dipendu Das; Yong Lu; Subhrajit Rout; Alexander W Schammel; Dane Holte; Baiwei Lin; Christine Gu; Hetal Sarvaiya; Jose Trinidad; Nicole Barbour; Amanda M Valdiosera; Joseph Sandoval; Christina Lee; Monette Aujay; Hanan Fernando; Anukriti Dhar; Holger Karsunky; Nicole Taylor; Marybeth Pysz; Julia Gavrilyuk
Journal:  Proc Natl Acad Sci U S A       Date:  2021-06-22       Impact factor: 11.205
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.